Literature DB >> 34942131

Idiopathic hypersomnia: does first to approval mean first-line treatment?

Lynn Marie Trotti1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34942131      PMCID： PMC9089235          DOI： 10.1016/S1474-4422(21)00419-1

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   59.935


× No keyword cloud information.
  7 in total

Review 1.  A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain.

Authors:  Andrea Furlan; Luis E Chaparro; Emma Irvin; Angela Mailis-Gagnon
Journal:  Pain Res Manag       Date:  2011 Sep-Oct       Impact factor: 3.037

2.  Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study.

Authors:  Yuichi Inoue; Toshiyuki Tabata; Naoji Tsukimori
Journal:  Sleep Med       Date:  2021-01-20       Impact factor: 3.492

3.  Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.

Authors:  Kiran Maski; Lynn Marie Trotti; Suresh Kotagal; R Robert Auger; James A Rowley; Sarah D Hashmi; Nathaniel F Watson
Journal:  J Clin Sleep Med       Date:  2021-09-01       Impact factor: 4.324

4.  Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study.

Authors:  Geert Mayer; Heike Benes; Peter Young; Marion Bitterlich; Andrea Rodenbeck
Journal:  J Sleep Res       Date:  2014-09-05       Impact factor: 3.981

5.  Determinants of antidepressant response: Implications for practice and future clinical trials.

Authors:  Jonathan Rabinowitz; Nomi Werbeloff; Francine S Mandel; Lauren Marangell; François Menard; Shitij Kapur
Journal:  J Affect Disord       Date:  2018-07-02       Impact factor: 4.839

6.  Medications for daytime sleepiness in individuals with idiopathic hypersomnia.

Authors:  Lynn M Trotti; Lorne A Becker; Catherine Friederich Murray; Romy Hoque
Journal:  Cochrane Database Syst Rev       Date:  2021-05-25

7.  Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.

Authors:  Yves Dauvilliers; Isabelle Arnulf; Nancy Foldvary-Schaefer; Anne Marie Morse; Karel Šonka; Michael J Thorpy; Emmanuel Mignot; Patricia Chandler; Rupa Parvataneni; Jed Black; Amanda Sterkel; Dan Chen; Franck Skobieranda; Richard K Bogan
Journal:  Lancet Neurol       Date:  2022-01       Impact factor: 59.935
  7 in total
  1 in total

1.  Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use.

Authors:  Young-A Heo
Journal:  CNS Drugs       Date:  2022-03-31       Impact factor: 6.497
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.